Due to important feedback received from patient groups and other stakeholders regarding the time allotted for public comments, ICER is re-opening the public comment period for the Draft Scoping Document on treatments for non-small cell lung cancer. In addition, ICER is extending the currently ongoing public comment period on the Draft Scoping Document for a review of treatments for plaque psoriasis. The comment period for both of these documents will now be open until Friday, July 8, 2016 at 5pm ET. Re-submissions from groups that have already submitted comments will be accepted.
ICER is committed to ensuring that each of ICER’s reviews benefits from the input of all stakeholders and adequately considers all perspectives of each topic. We hope this change improves the ability of members of the stakeholder community to provide their valuable insights and will ultimately improve the quality and actionability of our upcoming reports.
This extension comes as part of ICER’s continual efforts to improve our processes and ensure that our timelines meet the needs of all stakeholder groups. As part of this effort, ICER will be making additional changes to the timelines of future reviews to allow more time for engagement with patients, drug manufacturers, clinicians, payers, and other stakeholders. An announcement will be made in the coming weeks regarding these changes.
Any stakeholders interested in submitting comments on either the Draft Scoping Document on treatments for non-small cell lung cancer or the Draft Scoping Document on treatments for plaque psoriasis should email comments as an attached Word Document to email@example.com. All comments must be received by 5pm ET on Friday, July 8th, and must adhere to formatting requirements specified in ICER’s Public Comment Guide.